MARUHO CO., LTD.
- Country
- 🇯🇵Japan
- Ownership
- Private
- Established
- 1918-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.maruho.co.jp
Clinical Trials
58
Trial Phases
4 Phases
Drug Approvals
2
Drug Approvals
Pediatric Faropenem Sodium Granules
- Product Name
- 菲若姆
- Approval Number
- 国药准字HJ20191006
- Approval Date
- Nov 15, 2023
Pediatric Faropenem Sodium Granules
- Product Name
- 菲若姆
- Approval Number
- 国药准字HJ20180001
- Approval Date
- Nov 15, 2023
Clinical Trials
Distribution across different clinical trial phases (45 trials with phase data)• Click on a phase to view related trials
An Open-label, Phase 2 Study to Assess the Efficacy and Safety of Nemolizumab in Subjects With Systemic Sclerosis
- First Posted Date
- 2022-01-31
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Maruho Co., Ltd.
- Target Recruit Count
- 6
- Registration Number
- NCT05214794
- Locations
- 🇯🇵
The University of Tokyo Hospital, Tokyo, Japan
Omiganan Twice a Day (BID) in Patients With Facial Seborrheic Dermatitis
- First Posted Date
- 2018-09-28
- Last Posted Date
- 2019-05-01
- Lead Sponsor
- Maruho Co., Ltd.
- Target Recruit Count
- 36
- Registration Number
- NCT03688971
- Locations
- 🇳🇱
Centre for Human Drug Research, Leiden, Netherlands
Topical Ionic Contra-Viral Therapy in Actinic Keratosis
- Conditions
- Actinic Keratosis
- Interventions
- Drug: ICVT Topical GelDrug: Vehicle Topical Gel
- First Posted Date
- 2018-09-26
- Last Posted Date
- 2019-05-01
- Lead Sponsor
- Maruho Co., Ltd.
- Target Recruit Count
- 32
- Registration Number
- NCT03684772
- Locations
- 🇳🇱
Centre for Human Drug Research, Leiden, Netherlands
ICVT in HPV-induced Genital Lesions of Immunocompromised and Immunocompetent Patients
- First Posted Date
- 2017-11-07
- Last Posted Date
- 2019-03-20
- Lead Sponsor
- Maruho Co., Ltd.
- Target Recruit Count
- 28
- Registration Number
- NCT03334240
- Locations
- 🇳🇱
LUMC/Centre For Human Drug Research, Leiden, Netherlands
A Study to Evaluate the Safety and Efficacy of CLS006 Versus Vehicle in Subjects 2 Years of Age or Older With Cutaneous Common Warts
- First Posted Date
- 2017-08-23
- Last Posted Date
- 2023-09-14
- Lead Sponsor
- Maruho Co., Ltd.
- Target Recruit Count
- 491
- Registration Number
- NCT03259620
- Locations
- 🇺🇸
Burke Pharmaceutical Research, Hot Springs, Arkansas, United States
🇺🇸Dermatology Specialists, Inc., Oceanside, California, United States
🇺🇸West Dermatology Research Center, San Diego, California, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 6
- Next
News
Nielsen BioSciences Completes Phase 3 Enrollment for Novel Wart Treatment CANDIN
Nielsen BioSciences has completed enrollment of 325 subjects across the US and Japan in a Phase 3 trial evaluating CANDIN for common wart treatment, with results expected by end of 2025.
Rosacea Therapeutics Pipeline Shows Promise with Emerging Therapies
Over 25 companies are developing novel rosacea treatments, indicating a robust pipeline.
Rosacea Therapeutics: Emerging Therapies and Market Outlook
Over 25 companies are actively involved in developing novel rosacea treatments, indicating a robust pipeline.